Tweets
#OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
Mrinalini Dey @DrMiniDey ( View Tweet )
2 months 3 weeks ago
Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey @DrMiniDey ( View Tweet )
2 months 3 weeks ago
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey @DrMiniDey ( View Tweet )
2 months 3 weeks ago
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts.
POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA?
Yes: faster remission at week 4 (84.6% vs 15%)
But: equal at week 24
Prospective study in 46 patients
#POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
2 months 3 weeks ago
Top tips:
⭐️ Summarise the key facts but always provide the source
⭐️ Learn from mistakes to improve what you have
⭐️ Have high quality source material- scan multiple resources for the best quality info and latest news!
@RheumNow
#EULAR2026
Mrinalini Dey @DrMiniDey ( View Tweet )
2 months 3 weeks ago
What makes a good rheum learning platform?
@rheumnow’s Dr Jack Cush gives a masterclass in online learning and medical education, including the background to RheumNow.
#EULAR2026 @EMEUNET https://t.co/2cXpRXPK13
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
2 months 3 weeks ago
What do you think about this cartoon-style format for posters?
A- I love it!
B- It’s Ok but I prefer classic
As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients
#POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
2 months 3 weeks ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB
TheDaoIndex @KDAO2011 ( View Tweet )
2 months 3 weeks ago
Which imaging test has the highest carbon footprint???
Think wisely before prescribing 🩻
#EULAR2026
@RheumNow https://t.co/36Ej8smWRd
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
2 months 3 weeks ago
